Description
Vipadenant is a selective adenosine receptor antagonist, with Kis of 1.3 nM and 68 nM for A2A and A1, respectively. Vipadenant also reverses haloperidol-induced hypolocomotion in mice and rats. Formulations containing vipadenant are under clinical investigation for the treatment of symptoms associated with Parkinson’s disease
Vipadenant is a selective adenosine receptor antagonist, with Kis of 1.3 nM and 68 nM for A2A and A1, respectively. Vipadenant also reverses haloperidol-induced hypolocomotion in mice and rats. Formulations containing vipadenant are under clinical investigation for the treatment of symptoms associated with Parkinson’s disease
Alternate Name/Synonyms: BIIB014,3-[(4-amino-3-methylphenyl)methyl]-7-(2-furanyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-amine,CEB-4520,BIIB-014
Appearance: Crystalline solid
Formulation:
CAS Number: 442908-10-3
Structure Available?: Yes
Peptide sequence: N/S
Salt Form: No
Molecular Formula: C₁₆H₁₅N₇O
Molecular Weight: 321.3
Cell-Permeable?: TRUE
Purity: ≥98%
Solubilities: >40 mg/ml DMSO
Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Country of Origin: USA
Tag Line: A selective adenosine receptor antagonist
MDL Number:
PubChem CID: 21874557
SMILES: NC1=NC(C2=CC=CO2)=C3C(N(CC4=CC=C(N)C(C)=C4)N=N3)=N1
InChi: InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20)
InChi Key: HQSBCDPYXDGTCL-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20ºC |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |